Total net revenue of $15.2 million Adjusted EBITDA1 of $ (0.8) million, which includes EXXUA launch investments $30.0 million cash balance at December 31, 2025 Company launched EXXUA™ (gepirone) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results